So, Roche (RHHBY) has entered the obesity drug arena. The Swiss pharmaceutical giant, through its Genentech unit, just reported Phase 2 results for a candidate called petrelintide, developed in partnership with Zealand Pharma (ZEAL). The drug worked—it helped people lose weight. But in the high-stakes world of obesity treatments, "working" isn't always enough. You have to work better than the other guys, and on that front, Roche's new offering is still playing from behind.

The topline results from the ZUPREME-1 trial showed that once-weekly injections of petrelintide led to statistically significant weight loss after 28 weeks. The highest dose achieved about a 10.7% reduction from baseline. For context, that's a solid result. It's clinically meaningful. The study involved nearly 500 participants with obesity, and it hit its primary goal. So why isn't everyone cheering?

Because the current kings of the hill, Novo Nordisk's Wegovy and Eli Lilly's Zepbound, are setting a remarkably high bar. These GLP-1 drugs routinely show weight loss in the 15% to over 20% range. When you're competing in that league, an 11% result, while positive, can feel a bit underwhelming. It's like showing up to a home run derby and hitting a solid double. It's a good hit, but it's not going to win the contest.

Now, before we write off petrelintide entirely, let's talk about what it did well. The safety profile looks excellent. The drug's tolerability was comparable to a placebo, which is a big deal in a field where gastrointestinal side effects are common. The discontinuation rate due to adverse events was virtually identical between the drug and the placebo group (about 4.8% vs. 4.9%). Most side effects were mild, and there were no unexpected safety alarms. In fact, fewer people dropped out of the trial overall in the drug groups compared to the placebo group. That's a strong point in its favor.

The partnership behind this drug is no small thing, either. Back in 2025, Roche and Genentech cut a deal with Zealand Pharma that included a hefty $1.65 billion upfront payment. Zealand is also in line for up to $3.6 billion more in milestone payments. This is a serious, long-term commitment, not a side project.

So, what's next? The full data set will be presented at a medical conference soon. There's also a second Phase 2 trial (ZUPREME-2) looking at petrelintide in people with both obesity and type 2 diabetes, with results expected later in 2026. But perhaps the most interesting plan is to test petrelintide in combination with another Roche drug called CT-388. That study is slated to start later this year.

And CT-388 is worth a mention on its own. In a separate Phase 2 trial earlier this year, that drug—a dual GLP-1/GIP receptor agonist much like Lilly's Mounjaro and Zepbound—showed a whopping 22.5% weight loss over 48 weeks. That's right in the ballpark with the market leaders. The strategic thinking seems clear: maybe petrelintide isn't the single-agent champion, but perhaps it can be a valuable teammate in a combination therapy that aims for top-tier efficacy with an even better side-effect profile.

The market, however, was not in a mood for strategic nuance. Investors reacted swiftly to the news that petrelintide's efficacy, while good, wasn't great. Shares of Roche fell over 6% on Thursday. The reaction was even more brutal for Zealand Pharma, whose stock on the Copenhagen exchange cratered by more than 30% on Friday. The message from traders was pretty clear: in the gold rush for obesity treatments, showing up with a promising but second-tier candidate can be a tough sell.

The story here isn't that Roche failed. The drug did what it was supposed to do in this trial. The story is about the incredibly high standard that Novo Nordisk and Eli Lilly have set. Breaking into the obesity market now requires not just a safe and effective drug, but a potential blockbuster. Roche has two shots on goal with petrelintide and the more potent CT-388. The next phase of trials, especially the combination study, will determine if they can turn those shots into a score that finally challenges the league leaders.